Re-engineering Adenovirus Regulatory Pathways to Enhance Oncolytic Specificity and Efficacy

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2001 Nov 2

PMID 11689848

Citations 27

Authors

M Ramachandra

A Rahman

A Zou

M Vaillancourt

J A Howe

D Antelman

B Sugarman

G W Demers

H Engler

D Johnson

P Shabram

Affiliations

Soon will be listed here.

Abstract

Replicating adenoviruses may prove to be effective anticancer agents if they can be engineered to selectively destroy tumor cells. We have constructed a virus (01/PEME) containing a novel regulatory circuit in which p53-dependent expression of an antagonist of the E2F transcription factor inhibits viral replication in normal cells. In tumor cells, however, the combination of p53 pathway defects and deregulated E2F allows replication of 01/PEME at near wild-type levels. The re-engineered virus also showed significantly enhanced efficacy compared with extensively studied E1b-deleted viruses such as dl1520 in human xenograft tumor models.

Citing Articles

Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution.

Dawson L, Alshawabkeh M, Schroer K, Arakrak F, Ehrhardt A, Zhang W Eng Microbiol. 2024; 4(1):100140.

PMID: 39628785 PMC: 11611009. DOI: 10.1016/j.engmic.2024.100140.

Development and Characterization of an Oncolytic Human Adenovirus-Based Vector Co-Expressing the Adenovirus Death Protein and p14 Fusion-Associated Small Transmembrane Fusogenic Protein.

Poulin K, Clarkin R, Del Papa J, Parks R Int J Mol Sci. 2024; 25(22).

PMID: 39596515 PMC: 11594305. DOI: 10.3390/ijms252212451.

Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy.

Watanabe M, Nishikawaji Y, Kawakami H, Kosai K Viruses. 2021; 13(12).

PMID: 34960772 PMC: 8706629. DOI: 10.3390/v13122502.

Oncolytic Adenovirus in Cancer Immunotherapy.

Peter M, Kuhnel F Cancers (Basel). 2020; 12(11).

PMID: 33202717 PMC: 7697649. DOI: 10.3390/cancers12113354.

Backward Hopf bifurcation in a mathematical model for oncolytic virotherapy with the infection delay and innate immune effects.

Guo Y, Niu B, Tian J J Biol Dyn. 2019; 13(1):733-748.

PMID: 31532345 PMC: 8881057. DOI: 10.1080/17513758.2019.1667443.